An observational study in Sleep Apnea, sponsored by Acurable Ltd.. Recruiting at 2 sites in United Kingdom. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Acurable Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Sleep Apnea Syndromes with a site in United Kingdom — 7 open to participants now, 8 under way, 1 of them phase 3. Sleep Apnea Syndromes · United Kingdom.
Among the 36 studies in Sleep Apnea Syndromes with a site in United Kingdom, this one is the 4th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2020, is one of 14 observational ones, and was the 21st registered.
1,085 studies on the registry are indexed under Sleep Apnea Syndromes; 172 are open to participants now.
Browse Sleep Apnea Syndromes studies →7 of the 36 studies in Sleep Apnea Syndromes with a site in United Kingdom are open now. Recruiting first, the newest first:
Virginia Hawkins · Sites in United Kingdom
Ages 18+
Inspire Medical Systems, Inc. · Sites in United Kingdom, Austria, Belgium and 4 more countries
Ages 18+
NHS Greater Clyde and Glasgow · Sites in United Kingdom
Ages 1 min–16 yrs
Great Ormond Street Hospital for Children NHS Foundation Trust · Sites in United Kingdom
Ages 3–8 · Healthy volunteers
University Hospitals Coventry and Warwickshire NHS Trust · Sites in United Kingdom
Ages 18–100
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 119 Sleep Apnea Syndromes studies recruiting now, 58 (49%) set no upper age limit and 37 (31%) stop at 75 or younger; 25 take children under 18; 28 take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 3 · Phase 4 1
First in 2003; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 345 is above the median of 150 across 343 observational studies indexed under Sleep Apnea Syndromes.
Median enrollment 58 across the 22 interventional studies, 101 across the 14 observational. Of the 22 that completed or were terminated, 6 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
Acurable Ltd. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Acurable Ltd. has 1 study filed under Sleep Apnea Syndromes — fewer than ten, so there is no comparison to draw.
1 of the studies in Sleep Apnea Syndromes with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04031950Acurable Ltd.Clinical Evaluation of a Paediatric Sleep Diagnosis Technology | 2027-10-14 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies in Sleep Apnea Syndromes with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this project is to gather research data and subsequently evaluate algorithms to demonstrate clinical efficacy of a novel sleep apnoea detection system in the paediatric population.
The Study will involve patients who will have been referred for diagnosis of sleep apnoea, and the ultimate aim will be to compare the output of a novel apnoea detection system against in -clinic polysomnography or cardio-respiratory polygraphy, assess acceptance of the novel system in the home environment, assess validity in patients on ventilation, and on a cohort with BMI SDS of 3 or more.
The objective of this project is to gather research data and subsequently evaluate algorithms to demonstrate clinical efficacy of a novel sleep apnoea detection system in the paediatric population.
The Study will involve patients who will have been referred for diagnosis of sleep apnoea, and the ultimate aim will be to compare the output of a novel apnoea detection system against in -clinic polysomnography or cardio-respiratory polygraphy, assess acceptance of the novel system in the home environment, assess validity in patients on ventilation, and on a cohort with BMI SDS of 3 or more.
Patients who are referred to the clinic for the first and second group will spend one night's sleep in the clinic for group 1 and group 2. They will wear a polysomnography or cardio-respiratory polygraphy system (current goldstandard) and the novel device. At the end of the trial, we will compare the diagnosis results from both systems.
Patients who are referred for home diagnosis of sleep apnoea or overnight oximetry at home (group 3) will wear the standard clinical sleep test system and the novel device. At the end of the trial, the acceptability of the novel device will be assessed.
Patients who are on mechanical ventilation and referred for diagnosis of sleep apnoea in hospital or at home will wear the standard clinical sleep test system and the novel device. At the end of the trial, the validity of the diagnosis from the novel device will be assessed.
Patients who are referred for either at home or in hospital diagnosis of sleep apnoea with a BMI SDS score of 3 or more will wear the standard clinical sleep test system and the novel device. At the end of the trial, we will compare the diagnosis results from both systems.
The criteria were revised on the registry on Nov 18, 2026. See what changed
all children who have been referred for a sleep test.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Test group will wear PSG
Device: Novel wearable paediatric device
THis group will wear the novel device
Device: Novel wearable paediatric device
40 consecutive patients (plus/minus 30% to account for potential dropouts, invalid signals from the gold-standard), who will have been referred for at home diagnosis of sleep apnoea or overnight oximetry at home. Each site will recruit, in parallel, consecutive patients from the moment the first patient in this group is recruited at that site. Each subject whose parents are willing to take part in the trial and meets the inclusion criteria will be included in the study. Criteria for inclusion are children older than 8 years old and referral for overnight assessment for evaluation of possible sleep apnoea. Additionally, patients will be excluded from the study if the clinical team consider the child is too unwell or distressed to be approached or one of the exclusion criteria below. This patient cohort will be used to assess the acceptance of the AcuPebble technology in the home environment.
Device: Novel wearable paediatric device
30 patients will be recruited (plus/minus 30% to account for potential dropouts, invalid signals from the gold-standard), who are on mechanical ventilation and have been referred for diagnosis of sleep apnoea. Each subject whose parents are willing to take part in the trial and meets the inclusion criteria will be included in the study. Criteria for inclusion are children older than 1 year old, referral for overnight assessment for evaluation or monitoring of sleep apnoea, and being on mechanical ventilation while conducting the study in hospital, or over 8 years old, referral for overnight assessment for evaluation or monitoring of sleep apnoea, and being on mechanical ventilation while conducting the study at home. Patients will be excluded from the study if the clinical team consider the child is too unwell or distressed to be approached or one of the exclusion criteria below. These patients will be included in a final analysis of diagnostic validity.
Device: Novel wearable paediatric device
75 patients will be recruited (plus/minus 30% to account for potential dropouts, or invalid signals from the gold-standard), who have a BMI SDS score of 3 or more and have been referred for either at-home or in-hospital diagnosis of sleep apnoea. Each subject whose parents are willing to take part in the trial and meets the inclusion criteria will be included in the study. If their study is to take place in the home, only children who are older than 8 will be included. If their study is to take place in hospital, children over the age of 1 will be included. Patients will be excluded from the study if the clinical team consider the child is too unwell or distressed to be approached or one of the exclusion criteria below. These patients will be included in a final analysis of sensitivity and specificity for this cohort.
Device: Novel wearable paediatric device
The patient will wear the novel wearable paediatric device at the same time as polysmnography
Specificity and sensitivity of novel device
specificity and sensitivity of the output of the novel wearable device against polysomnography
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2020 (actual). Primary completion is estimated for Oct 2027, 91 months after the start.
Of 149 observational studies under Sleep Apnea Syndromes, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 83. This study's planned 91 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Oct 2025 → Oct 2027 and completion Dec 2025 → Oct 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acurable Ltd.